Approfondimenti generali
Neoplasie del polmone, Linee Guida AIOM, 2018. [Apri]
Planchard D, et al. Metastatic Non-Small-Cell Lung Cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018; 29: iv192–iv237 [Apri]
Postmus PE, et al. Early-Stage and Locally Advanced (non-metastatic) Non-Small-Cell Lung Cancer: ESMO Clinical Practice Guidelines. Ann Oncol 2017; 28: iv1–iv21. [Apri] A service of the U.S. National Institutes of Health [Apri]
Referenze bibliografiche specifiche
Reck M, et al. Primary PFS and safety analyses of a randomized phase III study of carboplatin + paclitaxel +/− bevacizumab, with or without atezolizumab in 1L non-squamous metastatic NSCLC (IMPOWER150). ESMO 2017, abs LBA1_PR [Apri]
Kowanetz M. Socinski M, et al. IMpower150: Efficacy of Atezolizumab Plus Bevacizumab and Chemotherapy in 1L Metastatic Nonsquamous NSCLC Across Key Subgroups. AACR Annual Meeting; April 14-18, 2018; Chicago, IL [Apri]
Cappuzzo F. Impower130: Progression-free survival (PFS) and safety analysis from a randomized phase 3 study of carboplatin + nab-paclitaxel (CnP) with or without atezolizumab (atezo) as first-line (1L) therapy in advanced non-squamous NSCLC. ESMO 2018 Abs LBA53 [Apri]
Fizazi K, Smith MR, Tombal B. Clinical Development of Darolutamide: A Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer. Clin Genitourin Cancer. 2018;16(5):332-340 [Apri]
Hussain M, Fizazi K, Saad F, et al. Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer. N Engl J Med. 2018;378(26):2465-2474 [Apri]